Home Cart Sign in  
Chemical Structure| 196078-29-2 Chemical Structure| 196078-29-2

Structure of Mepolizumab
CAS No.: 196078-29-2

Chemical Structure| 196078-29-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mepolizumab is a humanized IgG1 monoclonal antibody that prevents IL-5 from binding to its receptor by binding to IL-5. Mepolizumab has potential for research in eosinophilic diseases such as severe eosinophilic asthma.

Synonyms: SB 240563

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mepolizumab

CAS No. :196078-29-2
M.W : 146.24 kDa
SMILES Code : NONE
Synonyms :
SB 240563

Safety of Mepolizumab

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Mepolizumab

pyroptosis

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00244686 Hypereosinophilic Syndrome NO_LONGER_AVAILABLE - -
NCT03453021 Asthma; Eosinophilic COMPLETED 2017-10-31 University Hospital Grenoble, ... More >>La Tronche, 38700, France Less <<
NCT06348173 Asthma COMPLETED 2023-11-30 H?pital du Sacré-Coeur de Mont... More >>réal, Montréal, Quebec, H4J 1C5, Canada Less <<
NCT06107101 Chronic Rhinosinusitis With Na... More >>sal Polyps Less << PHASE4 NOT_YET_RECRUITING 2025-01-01 St. Paul's Sinus Centre, Vanco... More >>uver, British Columbia, V6Z 1Y6, Canada Less <<
NCT04512521 Asthma; Eosinophilic RECRUITING 2025-08-25 Hannover Medical School, Hanov... More >>er, Niedersachsen, 30625, Germany Less <<
NCT05063981 Asthma|Nasal Polyps|Sinusitis ... More >>Chronic Less << RECRUITING 2025-12-24 Istituti Clinici Scientifici M... More >>augeri IRCCS, Telese Terme, BN, 82037, Italy Less <<
NCT04550780 Asthma COMPLETED 2023-07-31 Uh Montpellier, Montpellier, 3... More >>4280, France Less <<
NCT04305678 Eosinophilic Fasciitis PHASE1 WITHDRAWN 2023-02-15 -
NCT03021304 Asthma PHASE3 COMPLETED 2017-08-08 GSK Investigational Site, Birm... More >>ingham, Alabama, 35243, United States|GSK Investigational Site, Los Angeles, California, 90025, United States|GSK Investigational Site, Cincinnati, Ohio, 45231, United States|GSK Investigational Site, Orangeburg, South Carolina, 29118-2040, United States|GSK Investigational Site, Sainte-Foy, Quebec, G1V 4G5, Canada|GSK Investigational Site, St. Charles-Borromee, Quebec, J6E 2B4, Canada|GSK Investigational Site, Amsterdam, 1105 AZ, Netherlands|GSK Investigational Site, Leeuwarden, 8934 AD, Netherlands|GSK Investigational Site, Zwolle, 8025 AB, Netherlands|GSK Investigational Site, Ekaterinburg, 620109, Russian Federation|GSK Investigational Site, Moscow, 123095, Russian Federation|GSK Investigational Site, Saint-Petersburg, 198328, Russian Federation|GSK Investigational Site, Link?ping, SE-581 85, Sweden|GSK Investigational Site, Lund, SE-221 85, Sweden|GSK Investigational Site, Stockholm, SE-141 86, Sweden Less <<
NCT00266565 Hypereosinophilic Syndromes|Eo... More >>sinophilic Gastroenteritis|Churg-Strauss Syndrome|Eosinophilic Esophagitis Less << PHASE1|PHASE2 COMPLETED 2025-04-05 Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229-3039, United States Less <<
NCT05895929 Chronic Rhinosinusitis With Na... More >>sal Polyps|Chronic Rhinosinusitis (Diagnosis) Less << EARLY_PHASE1 RECRUITING 2025-06-26 Johns Hopkins Bayview Medical ... More >>Center, Baltimore, Maryland, 21117, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States Less <<
NCT05139381 Asthma in Children ACTIVE_NOT_RECRUITING 2026-03-12 King's College Hospital, Londo... More >>n, SE5 9RS, United Kingdom Less <<
NCT04965636 Hypereosinophilic Syndrome PHASE3 RECRUITING 2024-09-16 GSK Investigational Site, Roch... More >>ester, Minnesota, 55905, United States|GSK Investigational Site, Cincinnati, Ohio, 45229, United States|GSK Investigational Site, Cleveland, Ohio, 44106, United States|GSK Investigational Site, Charleston, South Carolina, 29425, United States|GSK Investigational Site, Caba, Buenos Aires, C1028AAP, Argentina|GSK Investigational Site, Florencio Varela, Buenos Aires, 1888, Argentina|GSK Investigational Site, Florida, Buenos Aires, 1602, Argentina|GSK Investigational Site, Quilmes, Buenos Aires, 1878, Argentina|GSK Investigational Site, Sao Paulo, S?o Paulo, 05410-002, Brazil|GSK Investigational Site, Sorocaba, S?o Paulo, 18040-425, Brazil|GSK Investigational Site, Petach Tikva, 49202, Israel|GSK Investigational Site, Monterrey, Nuevo León, 64060, Mexico|GSK Investigational Site, Madrid, 28009, Spain|GSK Investigational Site, Ankara, 6230, Turkey|GSK Investigational Site, Izmir, 35100, Turkey|GSK Investigational Site, Kayseri, 38039, Turkey|GSK Investigational Site, London, SE5 9RS, United Kingdom Less <<
NCT01691859 Asthma PHASE3 COMPLETED 2017-05-31 GSK Investigational Site, Long... More >> Beach, California, 90808, United States|GSK Investigational Site, Riverside, California, 92506, United States|GSK Investigational Site, Denver, Colorado, 80206, United States|GSK Investigational Site, New Haven, Connecticut, 06520, United States|GSK Investigational Site, Albany, Georgia, 31707, United States|GSK Investigational Site, Lexington, Kentucky, 40508, United States|GSK Investigational Site, Winston-Salem, North Carolina, 27103, United States|GSK Investigational Site, Cleveland, Ohio, 44195, United States|GSK Investigational Site, Hershey, Pennsylvania, 17033, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15213, United States|GSK Investigational Site, Nashville, Tennessee, 37212, United States|GSK Investigational Site, Mar del Plata, Buenos Aires, B7600FZN, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, C1121ABE, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina|GSK Investigational Site, Mendoza, M5500CCG, Argentina|GSK Investigational Site, New Lambton, New South Wales, 2305, Australia|GSK Investigational Site, Adelaide, South Australia, 5000, Australia|GSK Investigational Site, Clayton, Victoria, 3168, Australia|GSK Investigational Site, Melbourne, Victoria, 3004, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia|GSK Investigational Site, Calgary, Alberta, T2N 4Z6, Canada|GSK Investigational Site, Vancouver, British Columbia, V5Z 1M9, Canada|GSK Investigational Site, Mississauga, Ontario, L5A 3V4, Canada|GSK Investigational Site, Quebec City, Quebec, G1V 4G5, Canada|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, 8207257, Chile|GSK Investigational Site, Valparaiso, Valparaíso, 2341131, Chile|GSK Investigational Site, Santiago, 8380453, Chile|GSK Investigational Site, Talcahuano, 4270918, Chile|GSK Investigational Site, Le Kremlin-Bicêtre Cedex, 94275, France|GSK Investigational Site, Marseille cedex 20, 13915, France|GSK Investigational Site, Montpellier cedex 5, 34295, France|GSK Investigational Site, Saint Pierre cedex, 97448, France|GSK Investigational Site, Ruedersdorf, Brandenburg, 15562, Germany|GSK Investigational Site, Frankfurt am Main, Hessen, 60596, Germany|GSK Investigational Site, Frankfurt, Hessen, 60596, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, 55131, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, 23552, Germany|GSK Investigational Site, Berlin, 10367, Germany|GSK Investigational Site, Berlin, 10717, Germany|GSK Investigational Site, Magdeburg, 39120, Germany|GSK Investigational Site, Cheongju, Chungcheongbuk-do, 361-711, Korea, Republic of|GSK Investigational Site, Suwon, Kyonggi-do, 443-721, Korea, Republic of|GSK Investigational Site, Lodz, 90-153, Poland|GSK Investigational Site, Wroclaw, 54-239, Poland|GSK Investigational Site, Bucharest, 011461, Romania|GSK Investigational Site, Bucharest, 050159, Romania|GSK Investigational Site, Iasi, 700115, Romania|GSK Investigational Site, Targu Mures, 540143, Romania|GSK Investigational Site, Barnaul, 656 045, Russian Federation|GSK Investigational Site, Chelyabinsk, 454106, Russian Federation|GSK Investigational Site, Kazan, 420008, Russian Federation|GSK Investigational Site, Moscow, 105 077, Russian Federation|GSK Investigational Site, Moscow, 123182, Russian Federation|GSK Investigational Site, Saint-Petersburg, 194354, Russian Federation|GSK Investigational Site, St'Petersburg, 191015, Russian Federation|GSK Investigational Site, Dnipropetrovsk, 49051, Ukraine|GSK Investigational Site, Donetsk, 83099, Ukraine|GSK Investigational Site, Kharkiv, 61035, Ukraine|GSK Investigational Site, Kiev, 03680, Ukraine|GSK Investigational Site, Kyiv, 03038, Ukraine|GSK Investigational Site, Leicester, Leicestershire, LE3 9QP, United Kingdom|GSK Investigational Site, London, EC1M 6BQ, United Kingdom|GSK Investigational Site, London, SW3 6HP, United Kingdom|GSK Investigational Site, Manchester, M23 9LT, United Kingdom|GSK Investigational Site, Southampton, SO16 6YD, United Kingdom Less <<
NCT02377427 Asthma PHASE2 COMPLETED 2018-01-31 GSK Investigational Site, San ... More >>Diego, California, 92123, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73112, United States|GSK Investigational Site, Medford, Oregon, 97504, United States|GSK Investigational Site, Madison, Wisconsin, 53792-9988, United States|GSK Investigational Site, Fukuoka, 811-1394, Japan|GSK Investigational Site, Hiroshima, 720-8520, Japan|GSK Investigational Site, Hiroshima, 721-8511, Japan|GSK Investigational Site, Wakayama, 646-8558, Japan|GSK Investigational Site, Lodz, 90-329, Poland|GSK Investigational Site, Tarnow, 33-100, Poland|GSK Investigational Site, Glasgow, G514TF, United Kingdom|GSK Investigational Site, Liverpool, L12 2AP, United Kingdom|GSK Investigational Site, London, SE5 9RS, United Kingdom|GSK Investigational Site, London, SW3 6NP, United Kingdom|GSK Investigational Site, Oxford, OX3 9DU, United Kingdom|GSK Investigational Site, Sheffield, S10 2TH, United Kingdom Less <<
NCT03099096 Asthma PHASE3 COMPLETED 2017-11-30 GSK Investigational Site, Birm... More >>ingham, Alabama, 35243, United States|GSK Investigational Site, Scottsdale, Arizona, 85251, United States|GSK Investigational Site, Los Angeles, California, 90025, United States|GSK Investigational Site, San Diego, California, 92123, United States|GSK Investigational Site, Colorado Springs, Colorado, 80907, United States|GSK Investigational Site, Aventura, Florida, 33180, United States|GSK Investigational Site, Miami, Florida, 33173, United States|GSK Investigational Site, Albany, Georgia, 31707, United States|GSK Investigational Site, Evansville, Indiana, 47713, United States|GSK Investigational Site, Baltimore, Maryland, 21236, United States|GSK Investigational Site, Saint Louis, Missouri, 63141, United States|GSK Investigational Site, Piscataway, New Jersey, 08854, United States|GSK Investigational Site, Rochester, New York, 14642, United States|GSK Investigational Site, Cincinnati, Ohio, 45231, United States|GSK Investigational Site, Medford, Oregon, 97504, United States|GSK Investigational Site, Orangeburg, South Carolina, 29118, United States|GSK Investigational Site, Woodville South, South Australia, 5011, Australia|GSK Investigational Site, Clayton, Victoria, 3169, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia|GSK Investigational Site, Sherwood Park, Alberta, T8H 0N2, Canada|GSK Investigational Site, Toronto, Ontario, M5T 3A9, Canada|GSK Investigational Site, Windsor, Ontario, N8X 2G1, Canada|GSK Investigational Site, St. Charles-Borromee, Quebec, J6E 2B4, Canada|GSK Investigational Site, Ruedersdorf, Brandenburg, 15562, Germany|GSK Investigational Site, Frankfurt, Hessen, 60389, Germany|GSK Investigational Site, Leipzig, Sachsen, 04357, Germany|GSK Investigational Site, Schleswig, Schleswig-Holstein, 24837, Germany|GSK Investigational Site, Berlin, 10717, Germany|GSK Investigational Site, Berlin, 12203, Germany|GSK Investigational Site, Chelyabinsk, 454021, Russian Federation|GSK Investigational Site, Voronezh, 394066, Russian Federation|GSK Investigational Site, Link?ping, SE-581 85, Sweden|GSK Investigational Site, Lund, SE-221 85, Sweden|GSK Investigational Site, Leicester, Leicestershire, LE3 9QP, United Kingdom|GSK Investigational Site, Bradford, BD96RJ, United Kingdom|GSK Investigational Site, Oxford, OX37LE, United Kingdom|GSK Investigational Site, Plymouth, PL6 8DH, United Kingdom|GSK Investigational Site, Southampton, SO16 6YD, United Kingdom Less <<
NCT04578171 Asthma UNKNOWN 2025-01-23 -
NCT03306043 Hypereosinophilic Syndrome PHASE3 COMPLETED 2019-12-30 GSK Investigational Site, La J... More >>olla, California, 92093, United States|GSK Investigational Site, New Haven, Connecticut, 06520, United States|GSK Investigational Site, Rochester, Minnesota, 55905, United States|GSK Investigational Site, Cincinnati, Ohio, 45229, United States|GSK Investigational Site, Mayfield Heights, Ohio, 44124, United States|GSK Investigational Site, Murray, Utah, 84107, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1028AAP, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, 7600, Argentina|GSK Investigational Site, Bruxelles, 1070, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, 40110-160, Brazil|GSK Investigational Site, Santo André - SP, S?o Paulo, 09080-110, Brazil|GSK Investigational Site, Sorocaba, S?o Paulo, 18040-425, Brazil|GSK Investigational Site, Lille Cedex, 59037, France|GSK Investigational Site, Nantes Cedex 1, 44093, France|GSK Investigational Site, Suresnes, 92151, France|GSK Investigational Site, Toulouse Cedex 9, 31059, France|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, 68167, Germany|GSK Investigational Site, Fulda, Hessen, 36043, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30625, Germany|GSK Investigational Site, Kirchheim unter Teck, 73230, Germany|GSK Investigational Site, Napoli, Campania, 80131, Italy|GSK Investigational Site, Firenze, Toscana, 50134, Italy|GSK Investigational Site, Guadalajara, Jalisco, 44100, Mexico|GSK Investigational Site, Monterrey, Nuevo León, 64060, Mexico|GSK Investigational Site, Villahermosa, Tabasco, 86035, Mexico|GSK Investigational Site, Krakow, 31-066, Poland|GSK Investigational Site, Lodz, 90-153, Poland|GSK Investigational Site, Bucharest, 010306, Romania|GSK Investigational Site, Targu Mures, 540327, Romania|GSK Investigational Site, Moscow, 125167, Russian Federation|GSK Investigational Site, Saint-Petersburg, 197341, Russian Federation|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Valencia, 46026, Spain|GSK Investigational Site, Leicester, LE3 9QP, United Kingdom Less <<
 

Historical Records

Categories